Abstract：Objective To investigate the composition of pathogens in the stable stage of bronchiectasis and the erythromycin treatment. Methods Totally 188 patients with bronchiectasis in our hospital from July 1 st, 2014 to July 1st, 2016 were randomly divided into the observation group and the control group, with 94 cases in each group. The control group was given conventional treatment (oral ambroxol hydrochloride), while the observation group received conventional treatment combined with erythromycin treatment. We observed the clinical efficacy of both groups after treatment including the immune function of T lymphocytes and the ratio of CD4＋, CD8＋, CD4＋/CD8＋, one second rate of pulmonary function (FEV1), the percentage of forced expiratory volume one second with predicted value (FEV1/FVC), the sputum volume and the composition of pathogenic bacteria. Results The total effective rate of the observation group (91.49%) was significantly higher than that of the control group (80.85%), and the difference was statistically significant (P<0.05). After the treatment, sputum volume reduced in both groups; patients without sputum in the observation group (82.98%) were significantly more than those in the control group (41.49%); patients with sputum volume less than 10ml (11.70%) in the observation group were significantly fewer than those in the control group (31.91%); patients with sputum volume from 10ml to 100ml (5.32%) in the observation group were significantly fewer than those in the control group (26.60%), and there was statistically significant difference (P<0.05). After the treatment, immune function of CD4＋, CD8＋, and CD4＋/CD8＋ in both groups improved; CD4＋increase (6.02±0.36) %in the observation group was significantly higher than that (0.98±0.20)%in the control group; CD8＋decrease (4.56±0.72)% in the observation group was significantly higher than that (1.25±0.37)%in the control group, CD4＋/CD8＋increase (0.60±0.13)% in the observation group was significantly higher than that (0.11± 0.01) % in the control group; there was statistical difference (P<0.05). After the treatment, FEV1 and FEV1/FVC levels of the lung function increased in the two groups; FEV1 increase (9.55±1.04) %and FEV1/FVC increase (10.26±1.14)% in the observation group were significantly higher than those (2.63±0.10)% and (2.20±0.24)% respectively) in the control group, and there was significant difference between two groups (P<0.05). Staphylococcus aureus (23.40%), Klebsiella pneumoniae (6.38%), Acinetobacter (0%), Pseudomonas aeruginosa (0%) in the observation group were significantly lower than those (56.39%, 17.02%, 12.77%, and 7.45% respectively) in the control group. The comparison between the two groups was statistically significant (P<0.05). Conclusion Erythromycin is effective in the treatment of bronchiectasis at stable stage. It can reduce the amount of expectoration, improve the immune function and pulmonary function of patients, reduce the positive rate of sputum bacteria and improve the dyspnea.
成旭明, 李艳敏, 何小花. 支气管扩张稳定期患者病原菌构成及红霉素治疗效果的统计分析[J]. 中国医院统计, 2017, 24(6): 407-410.
Cheng Xuming, Li Yanmin, He Xiaohua. Statistical analysis of the composition of pathogens and the treatment of erythromycin in the stable phase of bronchiectasis. journal1, 2017, 24(6): 407-410.
